BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 31388743)

  • 1. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.
    Lam J; Luttrell I; Ding L; Rezaei K; Chao JR; Chee Y; Olmos De Koo LC; Wen JC
    Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2489-2494. PubMed ID: 31388743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
    Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.
    Rothman AL; Beca FA; Tijerina JD; Schuman DM; Parrish RK; Vanner EA; Liu KC
    Ophthalmol Glaucoma; 2024; 7(3):260-270. PubMed ID: 38266962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Late and sustained intraocular pressure elevation related to intravitreal anti-VEGF injections: Cases requiring filtering surgery (French translation of the article)].
    Leleu I; Penaud B; Blumen-Ohana E; Rodallec T; Adam R; Laplace O; Akesbi J; Nordmann JP
    J Fr Ophtalmol; 2018 Nov; 41(9):789-801. PubMed ID: 30348599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
    Demirel S; Yanik O; Batioglu F; Ozmert E
    Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
    Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
    BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
    Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve implantation: a randomized control trial.
    Miraftabi A; Nilforushan N; Darghahi M; Alemzadeh SA; Parsamanesh M; Yadgari M
    Clin Exp Ophthalmol; 2018 Sep; 46(7):750-756. PubMed ID: 29573081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
    Good TJ; Kimura AE; Mandava N; Kahook MY
    Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular Pressure Changes and Vascular Endothelial Growth Factor Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry.
    Gabrielle PH; Nguyen V; Wolff B; Essex R; Young S; Hunt A; Gemmy Cheung CM; Arnold JJ; Barthelmes D; Creuzot-Garcher C; Gillies M;
    Ophthalmol Retina; 2020 Sep; 4(9):861-870. PubMed ID: 32574830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
    Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
    Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD.
    Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D
    Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.